Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Dermatologic 1CNS 1

Conditions

Sarcoma 1Osteosarcoma 1Neuroblastoma 1Melanoma 1

Interventions

Cyclophosphamide 10Temozolomide 8X-Rays 7Specimen Handling 7Irinotecan 7Phantoms, Imaging 6Magnetic Resonance Spectroscopy 6Filgrastim 6Carboplatin 5Biopsy 5fludarabine 4Nuclear Medicine Department, Hospital 4olaparib 3fludarabine phosphate 3etoposide phosphate 3dinutuximab 3Zoledronic Acid 3Oxaliplatin 3Nivolumab 3Ifosfamide 3Granulocyte Colony-Stimulating Factor 3Gemcitabine 3Etoposide 3Docetaxel 3ulixertinib 2tipifarnib 2tazemetostat 2selpercatinib 2palbociclib 2lorukafusp alfa 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Osteosarcoma × AP 1903 reagent × CNS × Clear all
NCT02107963 2024-05-16

A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
15 enrolled
CNSDermatologicSarcoma

Melanoma, Neuroblastoma, Sarcoma, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡